Comptes-rendus de sortie des patients : Questions médicales fréquentes
Nom anglais: Patient Discharge Summaries
Descriptor UI:D063886
Tree Number:N06.850.520.308.940.968.750
Termes MeSH sélectionnés :
Early Detection of Cancer
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Comptes-rendus de sortie des patients : Questions médicales les plus fréquentes",
"headline": "Comptes-rendus de sortie des patients : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Comptes-rendus de sortie des patients : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-11",
"dateModified": "2025-04-07",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Comptes-rendus de sortie des patients"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Dossiers médicaux",
"url": "https://questionsmedicales.fr/mesh/D008499",
"about": {
"@type": "MedicalCondition",
"name": "Dossiers médicaux",
"code": {
"@type": "MedicalCode",
"code": "D008499",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N06.850.520.308.940.968"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Comptes-rendus de sortie des patients",
"alternateName": "Patient Discharge Summaries",
"code": {
"@type": "MedicalCode",
"code": "D063886",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Christine Maria Schwarz",
"url": "https://questionsmedicales.fr/author/Christine%20Maria%20Schwarz",
"affiliation": {
"@type": "Organization",
"name": "Research Unit for Safety and Sustainability in Healthcare, c/o, Division of Plastic, Aesthetic and Reconstructive Surgery, Department of Surgery , Medical University of Graz, Graz, Austria."
}
},
{
"@type": "Person",
"name": "Magdalena Hoffmann",
"url": "https://questionsmedicales.fr/author/Magdalena%20Hoffmann",
"affiliation": {
"@type": "Organization",
"name": "Research Unit for Safety and Sustainability in Healthcare, c/o, Division of Plastic, Aesthetic and Reconstructive Surgery, Department of Surgery , Medical University of Graz, Graz, Austria. magdalena.hoffmann@medunigraz.at."
}
},
{
"@type": "Person",
"name": "Gerald Sendlhofer",
"url": "https://questionsmedicales.fr/author/Gerald%20Sendlhofer",
"affiliation": {
"@type": "Organization",
"name": "Research Unit for Safety and Sustainability in Healthcare, c/o, Division of Plastic, Aesthetic and Reconstructive Surgery, Department of Surgery , Medical University of Graz, Graz, Austria."
}
},
{
"@type": "Person",
"name": "Thomas R Campion",
"url": "https://questionsmedicales.fr/author/Thomas%20R%20Campion",
"affiliation": {
"@type": "Organization",
"name": "Department of Population Health, Weill Cornell Medicine, New York, NY 10065, United States."
}
},
{
"@type": "Person",
"name": "Rebecca Brundin-Mather",
"url": "https://questionsmedicales.fr/author/Rebecca%20Brundin-Mather",
"affiliation": {
"@type": "Organization",
"name": "Department of Critical Care Medicine, University of Calgary, Calgary T2N 4Z6, Alberta, Canada."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "A Clinical Analysis of Prognosis and Patient-Reported Outcomes of Oncoplastic Breast-Conserving Surgery for Early Breast Cancer: A Retrospective Cohort Study.",
"datePublished": "2023-10-11",
"url": "https://questionsmedicales.fr/article/37821554",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00266-023-03631-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "Lobar or sublobar resection for early-stage second primary lung cancer ≤ 3 cm in size: a SEER population-based study.",
"datePublished": "2023-09-19",
"url": "https://questionsmedicales.fr/article/37725243",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00432-023-05396-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "An optimal dose-fractionation for stereotactic body radiotherapy in peripherally, centrally and ultracentrally located early-stage non-small lung cancer.",
"datePublished": "2023-09-10",
"url": "https://questionsmedicales.fr/article/37691151",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/1759-7714.15071"
}
},
{
"@type": "ScholarlyArticle",
"name": "Survival Outcomes and Efficacy of Platinum in Early Breast Cancer Patients with Germline BRCA1 or BRCA2 Mutation: A Multicenter Retrospective Cohort Study.",
"datePublished": "2023-09-04",
"url": "https://questionsmedicales.fr/article/37692097",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2147/BCTT.S423330"
}
},
{
"@type": "ScholarlyArticle",
"name": "The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative.",
"datePublished": "2023-08-16",
"url": "https://questionsmedicales.fr/article/37595684",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jtho.2023.08.016"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Environnement et santé publique",
"item": "https://questionsmedicales.fr/mesh/D004778"
},
{
"@type": "ListItem",
"position": 3,
"name": "Santé publique",
"item": "https://questionsmedicales.fr/mesh/D011634"
},
{
"@type": "ListItem",
"position": 4,
"name": "Méthodes épidémiologiques",
"item": "https://questionsmedicales.fr/mesh/D004812"
},
{
"@type": "ListItem",
"position": 5,
"name": "Collecte de données",
"item": "https://questionsmedicales.fr/mesh/D003625"
},
{
"@type": "ListItem",
"position": 6,
"name": "Documents",
"item": "https://questionsmedicales.fr/mesh/D011996"
},
{
"@type": "ListItem",
"position": 7,
"name": "Dossiers médicaux",
"item": "https://questionsmedicales.fr/mesh/D008499"
},
{
"@type": "ListItem",
"position": 8,
"name": "Comptes-rendus de sortie des patients",
"item": "https://questionsmedicales.fr/mesh/D063886"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Comptes-rendus de sortie des patients - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Comptes-rendus de sortie des patients",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Comptes-rendus de sortie des patients",
"description": "Quels diagnostics sont souvent notés dans un compte-rendu ?\nComment le diagnostic est-il confirmé dans le rapport ?\nQuelle est l'importance du diagnostic dans le compte-rendu ?\nLes diagnostics sont-ils classés dans le compte-rendu ?\nComment les diagnostics influencent-ils le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D063886?mesh_terms=Early+Detection+of+Cancer&page=998#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Comptes-rendus de sortie des patients",
"description": "Quels symptômes sont souvent mentionnés ?\nComment les symptômes sont-ils évalués ?\nLes symptômes changent-ils après le traitement ?\nLes symptômes sont-ils classés par gravité ?\nComment les symptômes influencent-ils le suivi ?",
"url": "https://questionsmedicales.fr/mesh/D063886?mesh_terms=Early+Detection+of+Cancer&page=998#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Comptes-rendus de sortie des patients",
"description": "Quelles mesures préventives sont recommandées ?\nComment la prévention est-elle abordée dans le rapport ?\nLa prévention est-elle personnalisée ?\nQuels conseils de prévention sont souvent inclus ?\nLa prévention est-elle suivie après la sortie ?",
"url": "https://questionsmedicales.fr/mesh/D063886?mesh_terms=Early+Detection+of+Cancer&page=998#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Comptes-rendus de sortie des patients",
"description": "Quels types de traitements sont documentés ?\nComment les traitements sont-ils justifiés ?\nLes traitements sont-ils suivis d'effets secondaires ?\nComment les traitements sont-ils planifiés ?\nLes traitements sont-ils adaptés après la sortie ?",
"url": "https://questionsmedicales.fr/mesh/D063886?mesh_terms=Early+Detection+of+Cancer&page=998#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Comptes-rendus de sortie des patients",
"description": "Quelles complications peuvent survenir après la sortie ?\nComment les complications sont-elles signalées ?\nLes complications sont-elles documentées dans le rapport ?\nComment prévenir les complications après la sortie ?\nLes complications influencent-elles le suivi ?",
"url": "https://questionsmedicales.fr/mesh/D063886?mesh_terms=Early+Detection+of+Cancer&page=998#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Comptes-rendus de sortie des patients",
"description": "Quels facteurs de risque sont souvent identifiés ?\nComment les facteurs de risque sont-ils évalués ?\nLes facteurs de risque influencent-ils le traitement ?\nLes facteurs de risque sont-ils notés dans le compte-rendu ?\nComment réduire les facteurs de risque après la sortie ?",
"url": "https://questionsmedicales.fr/mesh/D063886?mesh_terms=Early+Detection+of+Cancer&page=998#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Quels diagnostics sont souvent notés dans un compte-rendu ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les diagnostics incluent des maladies aiguës, chroniques et des complications post-opératoires."
}
},
{
"@type": "Question",
"name": "Comment le diagnostic est-il confirmé dans le rapport ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic est confirmé par des examens cliniques, des tests de laboratoire et des imageries."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance du diagnostic dans le compte-rendu ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il guide le suivi médical et les traitements à administrer après la sortie."
}
},
{
"@type": "Question",
"name": "Les diagnostics sont-ils classés dans le compte-rendu ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont souvent classés par ordre de gravité ou de chronologie."
}
},
{
"@type": "Question",
"name": "Comment les diagnostics influencent-ils le traitement ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils déterminent les protocoles de traitement et les médicaments prescrits."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont souvent mentionnés ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleur, fièvre, fatigue et autres signes cliniques pertinents."
}
},
{
"@type": "Question",
"name": "Comment les symptômes sont-ils évalués ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont évalués par l'examen physique et les antécédents médicaux du patient."
}
},
{
"@type": "Question",
"name": "Les symptômes changent-ils après le traitement ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le compte-rendu note souvent l'évolution des symptômes post-traitement."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils classés par gravité ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être classés en fonction de leur impact sur la santé du patient."
}
},
{
"@type": "Question",
"name": "Comment les symptômes influencent-ils le suivi ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils orientent les recommandations de suivi et les consultations nécessaires."
}
},
{
"@type": "Question",
"name": "Quelles mesures préventives sont recommandées ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les mesures incluent vaccinations, conseils diététiques et exercices physiques."
}
},
{
"@type": "Question",
"name": "Comment la prévention est-elle abordée dans le rapport ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est abordée par des recommandations spécifiques basées sur le diagnostic."
}
},
{
"@type": "Question",
"name": "La prévention est-elle personnalisée ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est souvent adaptée aux antécédents médicaux et au mode de vie du patient."
}
},
{
"@type": "Question",
"name": "Quels conseils de prévention sont souvent inclus ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des conseils sur l'alimentation, l'exercice et l'arrêt du tabac sont fréquents."
}
},
{
"@type": "Question",
"name": "La prévention est-elle suivie après la sortie ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le suivi des mesures préventives est souvent recommandé lors des consultations."
}
},
{
"@type": "Question",
"name": "Quels types de traitements sont documentés ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent médications, interventions chirurgicales et thérapies physiques."
}
},
{
"@type": "Question",
"name": "Comment les traitements sont-ils justifiés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont justifiés par les diagnostics et l'évolution des symptômes du patient."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils suivis d'effets secondaires ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les effets secondaires potentiels sont souvent notés pour chaque traitement."
}
},
{
"@type": "Question",
"name": "Comment les traitements sont-ils planifiés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont planifiés en fonction des besoins individuels et des protocoles médicaux."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils adaptés après la sortie ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des ajustements peuvent être nécessaires en fonction de l'évolution du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après la sortie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent infections, douleurs persistantes et complications liées aux traitements."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles signalées ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont signalées par des observations cliniques et des tests de suivi."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles documentées dans le rapport ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont souvent documentées pour informer le suivi médical."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications après la sortie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par des soins appropriés et le respect des recommandations médicales."
}
},
{
"@type": "Question",
"name": "Les complications influencent-elles le suivi ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent nécessiter des consultations supplémentaires et des ajustements de traitement."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont souvent identifiés ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, les antécédents familiaux et les habitudes de vie."
}
},
{
"@type": "Question",
"name": "Comment les facteurs de risque sont-ils évalués ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont évalués par l'anamnèse et des tests de dépistage spécifiques."
}
},
{
"@type": "Question",
"name": "Les facteurs de risque influencent-ils le traitement ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent orienter les choix thérapeutiques et les recommandations de suivi."
}
},
{
"@type": "Question",
"name": "Les facteurs de risque sont-ils notés dans le compte-rendu ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont souvent notés pour une meilleure gestion des soins futurs."
}
},
{
"@type": "Question",
"name": "Comment réduire les facteurs de risque après la sortie ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "La réduction passe par des changements de mode de vie et un suivi médical régulier."
}
}
]
}
]
}
Approximately 25-30% of patients suffer from breast deformity and/or asymmetry after conventional breast-conserving surgery (CBCS). Generally, it is thought that oncoplastic breast-conserving surgery ...
A total of 143 patients were included in this retrospective cohort study; 53 underwent OBCS and 90 underwent CBCS. The resected weight, complications, esthetic results, patient satisfaction, and recur...
The mean age of the patients in OBCS group was 43.8 years. This was younger than that in CBCS group (49.1 years, p < 0.001). Postoperative complications (11.3% vs. 8.9%, p = 0.64) and re-excision (5.7...
Although OBCS has the better aesthetic outcomes and identical oncological safety in comparison with CBCS, the sexual and physical well-being in OBCS are not improved for Asian patients. Hence, choosin...
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Inst...
Surgical strategy for second primary lung cancer (SPLC) may be more conservative due to influence of first primary lung cancer (FPLC). The optimal surgical method for SPLC warrants discussion. We aime...
A retrospective study was conducted using data from the Surveillance, Epidemiology and End Results database between 2004 and 2018, and data of patients with early-stage SPLC who underwent secondary su...
A total of 714 patients who met the study entry criteria were enrolled, including 476 patients in the sublobar resection group (66.67%) and 238 patients in the lobar resection group (33.33%). There wa...
The OS of sublobar resection was not significantly different from that of lobar resection for early-stage SPLC. For SPLC with a 2-3 cm tumor size, lobar resection is more advantageous than sublobar re...
Stereotactic body radiotherapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), is commonly used in inoperable patients with early-stage non-small lung cancer (NSCLC). This treatment h...
The study aimed to compare the survival outcomes and efficacy of platinum in early breast cancer patients with BRCA1 and BRCA2 mutations....
Patients diagnosed with stage I-III breast cancer and carrying germline pathogenic/likely pathogenic BRCA mutations in three medical institutions in China from April 2016 to January 2021 were retrospe...
One hundred and sixty-nine patients with BRCA mutations were enrolled, including BRCA1 mutation (53.3%, n = 90) and BRCA2 mutation (46.7%, n = 79). The median age was 39 years, and most patients (68.1...
Similar survival outcomes were observed in early breast cancer patients with BRCA1 and BRCA2 mutation, though they had different biological characteristics. Patients with BRCA1 mutations are more bene...
With global adoption of computed tomography (CT) lung cancer screening, there is increasing interest to use artificial intelligence (AI) deep learning methods to improve the clinical management proces...
In this second phase of the initiative, metadata and screening CT scans from two time points were collected from 100 screening participants in seven countries. An automated deep learning AI lung segme...
A total of 1394 CTs were collected from 697 participants. The LAV950 quantitative emphysema metric was found to be potentially useful in distinguishing lung cancer from benign cases using a combined s...
These initial experiments revealed that ELIC can support deep learning AI and quantitative imaging analyses on diverse and globally distributed cloud-based data sets....
Access to early phase trials for children with relapsed, refractory or progressive (RRPD) cancer is limited in Canada. Patients and families face barriers to access trials, which are poorly understood...
Oncology patients ≤18 years at diagnosis who later had RRPD were identified retrospectively via registry at the only quaternary paediatric oncology centre in British Columbia (BC). We determined if di...
Between January 2015 and July 2021, 266 patients experienced 396 RRPD events. Seventy-five patients (28.2%) were eligible for an early phase trial at least once. At first eligible event, 61 patients (...
Children in BC with cancer and RRPD have limited access to early phase trials. Distance was not predictive of enrolment, suggesting that families travel to access therapy....
Ovarian cancer (OV) is the most lethal gynecological malignancy and requires improved early detection methods and more effective intervention to achieve a better prognosis. The lack of sensitive and n...
The aim of this work was to prospectively evaluate the toxicity and cosmetic outcomes of 5-fraction, stereotactic, accelerated partial breast irradiation (APBI)....
This prospective observational cohort study enrolled women who underwent APBI for invasive carcinoma or carcinoma in situ of the breast. APBI was delivered using a CyberKnife M6 robotic radiosurgery s...
In total, 204 patients (APBI, n = 103; WBI, n = 101) were enrolled. Regarding patient-reported outcomes, the APBI group reported significantly less skin dryness (6.9% vs 18.3%; P = .015), radiation sk...
Stereotactic APBI was associated with less fibrosis in the uninvolved breast quadrants than WBI. Patients showed minimal toxicity and no detrimental effects on cosmesis after APBI....
Synchronous multiple primary colorectal cancer (SMPCC) involves the simultaneous occurrence of 2 or more independent primary malignant tumors in the colon or rectum. Although SMPCC is rare, it results...
The clinical factors and survival outcomes of SMPCC patients registered on the Surveillance, Epidemiology, and End Results (SEER) database between 2000 and 2017 were extracted. The patients were divid...
A total of 4386 SMPCC patients were enrolled in the study and randomly assigned to the training (n = 3070) and validation (n = 1316) cohorts. The multivariate logistic analysis identified age, chemoth...
Our nomogram can provide a simple and accurate tool for clinicians to predict the risk of early death in SMPCC patients undergoing surgery and could be used to optimize the treatment according to the ...